ArticleBritish journal of cancer2012
Prediction of early death among patients enrolled in phase I trials: development and validation of a new model based on platelet count and albumin.
Article in British journal of cancer, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Evolving or immutable - phase I solid tumor trials in the era of precision oncology.Investigational new drugs · 2024Pooled it
- Evolving or Immutable - Phase I Solid Tumor Trials in the Era of Precision Oncology.Research square · 2024Article
- Genetic variation of platelet glycoprotein VI and the risk of venous thromboembolism.Haematologica · 2020Article
- Plasma total cell-free DNA is a prognostic biomarker of overall survival in metastatic solid tumour patients.British journal of cancer · 2019Article
- Phase i trials in melanoma: A framework to translate preclinical findings to the clinic.European journal of cancer (Oxford, England : 1990) · 2016Article
- Predictors of early treatment discontinuation in patients enrolled on Phase I oncology trials.Oncotarget · 2015Article
- The neutrophil-lymphocyte ratio and its utilisation for the management of cancer patients in early clinical trials.British journal of cancer · 2015Article
- The role of palliative chemotherapy in hospitalized patients.Current oncology (Toronto, Ont.) · 2014Article
- Nomogram to predict cycle-one serious drug-related toxicity in phase I oncology trials.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2014Article
- Platelet count measured prior to cancer development is a risk factor for future symptomatic venous thromboembolism: the Tromsø Study.PloS one · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSelecting patients with 'sufficient life expectancy' for Phase I oncology trials remains challenging. The Royal Marsden Hospital Score (RMS) previously identified high-risk patients as those with ≥ 2 of the following: albumin <35 g l(-1); LDH > upper limit of normal; >2 metastatic sites. This study developed an alternative prognostic model, and compared its performance with that of the RMS.
methodsThe primary end point was the 90-day mortality rate. The new model was developed from the same database as RMS, but it used Chi-squared Automatic Interaction Detection (CHAID). The ROC characteristics of both methods were then validated in an independent database of 324 patients enrolled in European Organization on Research and Treatment of Cancer Phase I trials of cytotoxic agents between 2000 and 2009.
resultsThe CHAID method identified high-risk patients as those with albumin <33 g l(-1) or ≥ 33 g l(-1), but platelet counts ≥ 400.000 mm(-3). In the validation data set, the rates of correctly classified patients were 0.79 vs 0.67 for the CHAID model and RMS, respectively. The negative predictive values (NPV) were similar for the CHAID model and RMS.
conclusionThe CHAID model and RMS provided a similarly high level of NPV, but the CHAID model gave a better accuracy in the validation set. Both CHAID model and RMS may improve the screening process in phase I trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.